Komori
Astena Holdings (8095) · InitiativeAdvanced

Partial Sale of Investment Securities Holdings

First written in FY2016. 4 of 10 entries say "Advanced", first in FY2020. Latest entry: FY2024.

10entries
9years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2017 – FY2020-Q1AdvancedFY2020 – FY20242017: 220172018: 120182019: 220192020: 120202021: 120212022: 020222023: 220232024: 020242025: 1
Same theme, other companies
Recognition of gains on sales of investment securities and shares in affiliated companiesA theme 315 companies write about · 1 as a headwind · 338 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 181 companies compared. The sentences above are computed from all 181.Comparing 200 of the theme's 342 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2024AdvancedAnnual report

    「Regarding the Company's cross-shareholdings, the Company has a policy of selling them to the fullest extent possible. After management regularly verifies and deliberates on the purpose of holding them, their effectiveness and their economic rationale, the Company makes its decisions.」

    The Company sold 4 issues held for strategic purposes and recorded a gain on sale of investment securities of ¥315.803 million.
  2. FY2023-Q3AdvancedAnnual report

    「This resulted from the sale of 2 issues held for strategic purposes.」

    The Company sold 2 issues held for strategic purposes and recorded a gain on sale of investment securities of ¥51.052 million.
  3. FY2022AdvancedAnnual report

    「Regarding the Company's cross-shareholdings, the Company has a policy of selling them to the fullest extent possible. After regularly verifying and deliberating on the purpose of holding them, their effectiveness and their economic rationale at meetings of the Board of Directors, the Company makes its decisions.」

    The Company continued its policy of reducing cross-shareholdings, selling 7 issues held for strategic purposes during the current consolidated fiscal year and recording a gain on sale of ¥261.588 million.
  4. FY2020AdvancedAnnual report

    「Gain on sale of investment securities 17,412」

    The Company sold investment securities and recorded sale proceeds of ¥48.753 million and a gain on sale of ¥17.412 million.
  5. FY2020-Q1Increase in gains on sales of investment securitiesAnnual report

    「Gain on sale of investment securities 11,594」

    The Company recorded a gain on sale of investment securities of ¥11.594 million in the first quarter, up from ¥1.250 million in the same period of the previous year.
  6. FY2019-Q3RestatedAnnual report

    「Gain on sale of investment securities 1,250」

    It remains confirmed that the Company recorded a gain on sale of investment securities of ¥1.250 million in the cumulative third-quarter period.
  7. FY2019-Q1Recognition of Gain on Sale of Investment SecuritiesAnnual report

    「Gain on sale of investment securities 1,250」

    The Company recorded a gain on sale of investment securities of ¥1.250 million in the first quarter.
  8. FY2017RestatedAnnual report

    「Gain on sale of investment securities ¥223.738 million」

    Regarding the partial sale of investment securities decided in the previous fiscal year, the Company recorded sale proceeds of ¥263.530 million and a gain on sale of ¥223.738 million for the full fiscal year.
  9. FY2017-Q1AchievedAnnual report

    「Gain on sale of investment securities 219,932」

    Regarding the partial sale of investment securities decided in the previous fiscal year, a gain on sale of ¥219.932 million was recorded in the first quarter.
  10. FY2016First statedAnnual report

    「The Company decided to sell part of the investment securities it held and entered into a share transfer agreement. As a result of this transaction, the Company plans to record a gain on the sale of investment securities of ¥219 million as extraordinary income for the consolidated fiscal year ending November 2017.」

    The Company decided to sell part of its investment securities and planned to record a gain on sale of ¥219 million for the fiscal year ending November 2017.
Moved together

"Overseas Expansion and Product Development in Chemicals, New Equipment and Optimal-Site Production" moved the same way as this thread, in the same document, in 5 of its 10 moves.

554443★123456
  1. ★This thread
  2. 1Overseas Expansion and Product Development in Chemicals, New Equipment and Optimal-Site Production5×
  3. 2Expanding Sales of Generic Pharmaceutical Ingredients and New Materials Through Customer Proposals5×
  4. 3Sharp Decline in Chemicals Business Revenue and Widening Operating Loss4×
  5. 4Stable Supply of Pharmaceuticals, Capital Investment and Production Efficiency Improvements4×
  6. 5Reduction of Policy-Held Shares and Regular Board Review4×
  7. 6Creating and Nurturing a Fifth Core Business3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Astena Holdings yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Partial Sale of Investment Securities Holdings | Astena Holdings Co.,Ltd. (8095) | Komori